Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Material AgreementItem 1.01 · 8-KLOW RiskPositive

Pacira Biosciences, Inc.

zimmerbiomet.com
Filed: Jun 28, 2026Warsaw, IndianaCIK: 0001396814Information Technology
Watch CompanyView on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Pacira Biosciences divested its CryoTech subsidiary to Zimmer, Inc. for up to $140 million to streamline operations and focus on core business areas. This strategic divestiture removes a non-core asset and generates significant cash proceeds.

Key Takeaways

Pacira sold wholly owned subsidiary Pacira CryoTech, Inc. and related cryoanalgesia device assets including iovera® to Zimmer, Inc.

Total transaction value is up to $140 million with $70 million upfront payment and contingent consideration subject to typical adjustments

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 28, 2026
Item1.01
CategoryMaterial Agreement
CIK0001396814
Accession #pcrx-20260628
Risk LevelLOW
SentimentPositive
Signalopportunity
Topics
divestiture

What This Means

The company entered into a significant agreement that could materially affect its business. This often signals new partnerships, licensing deals, or major contracts.
View Full Filing on SEC.govBrowse More Filings